GeneLink Reports 2012 Financial Results
"With new and reinvigorated marketing partners, as well as fresh products and market opportunities, GeneLink believes 2013 offers new opportunities for growth in the consumer rapidly maturing genomics marketplace."
Dr. Kasten added, "In a development which should not be overlooked, GeneLink completed over 18 months of cooperation with the Federal Trade Commission (the "Commission") when it entered into a proposed Consent Agreement with the staff of the Commission. The tentative agreement, which awaits final approval by the Commissioners, does not provide for any financial obligations by the Company and provides us with useful guidance moving forward. To the best of our knowledge, GeneLink is the first consumer genetics company to negotiate such an agreement, a testament to the strength of our Scientific Advisory Board and the integrity of our approach."
About GeneLink Biosciences, Inc.:
GeneLink Biosciences is an 18-year old leading biosciences company specializing in consumer genomics. GeneLink's patented technologies include proprietary DNA test assessments linked to personalized health, beauty and wellness applications and products. Its DNA assessments provide information that enables the customization of nutritional and skincare products designed and manufactured for each individual consumer's wellness needs. For more information visit www.genelinkbio.com.This release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in the press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GeneLink disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future developments or otherwise. SOURCE GeneLink, Inc.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV